Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 4/20 | 0.50 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.46 |
| ▸ | TFPI | P10646 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974502 | 0.90 | KISS1R (0.48) | VIPR1VIPR2BACE1KISS1RGRIN2D | |
| SCHEMBL30712884 | 0.89 | VIPR1 (0.57) | VIPR1VIPR2BACE1GRIN2DGRIN3B | |
| SCHEMBL31318575 | 0.89 | VIPR1 (0.53) | VIPR1VIPR2BACE1GRIN2DGRIN3B | |
| SCHEMBL29965025 | 0.88 | VIPR1 (0.56) | VIPR1VIPR2BACE1GRIN2DGRIN3B | |
| SCHEMBL30662325 | 0.88 | VIPR1 (0.58) | VIPR1VIPR2BACE1GRIN2DGRIN3B | |
| SCHEMBL4515922 | 0.88 | ENPEP (0.48) | VIPR1VIPR2BACE1KISS1RGRIN2D | |
| SCHEMBL4515920 | 0.88 | ENPEP (0.48) | VIPR1VIPR2BACE1KISS1RGRIN2D | |
| SCHEMBL30182730 | 0.87 | NPY4R (0.46) | VIPR1TFPI | |
| SCHEMBL29489382 | 0.87 | GRIN2D (0.59) | VIPR1VIPR2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30863950 | 0.87 | TASP1 (0.49) | VIPR1VIPR2BACE1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11291407-B2 | Detection of high risk drusen | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291407-B2 | Detection of high risk drusen | EXOSC4, EXOSC5, EXOSC10 | VIPR1 1035/4885VIPR2 1841/4885BACE1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.